Functional state of patients with heterotaxy syndrome following the Fontan operation

Andrew M Atz1, Meryl S Cohen, Lynn A Sleeper

  • 1Department of Pediatrics, Division of Cardiology, Medical University of South Carolina, Children's Hospital, Charleston, South Carolina 29425, United States of America. atzam@musc.edu

Cardiology in the Young
|December 6, 2007
PubMed

Insights

Children with heterotaxy syndromes undergoing the Fontan procedure have unique anatomical differences but similar functional health and exercise outcomes compared to other survivors. This study highlights their specific characteristics post-Fontan operation.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease
  • Cardiovascular Surgery

Background:

  • Heterotaxy syndromes are associated with poorer outcomes in children undergoing surgical palliation.
  • Previous studies suggest heterotaxy is a risk factor for mortality and morbidity after the Fontan procedure.
  • Limited data exists on the functional status of heterotaxy survivors post-Fontan operation.

Purpose of the Study:

  • To evaluate the functional state of pediatric patients with heterotaxy following the Fontan procedure.
  • To compare medical and patient characteristics between heterotaxy and non-heterotaxy survivors of the Fontan procedure.

Main Methods:

  • Multicentric cross-sectional study of 546 Fontan procedure survivors (aged 6-18 years).
  • Evaluations included echocardiography, exercise testing, ECG, MRI, and health status questionnaires.
  • 42 patients (8%) had heterotaxy; characteristics were compared to 504 without heterotaxy.

Main Results:

  • Heterotaxy patients had later Fontan and volume-unloading surgery, and different ventricular/valvar morphology and venous abnormalities.
  • Higher incidence of prior pulmonary vein surgery and atrial arrhythmias in heterotaxy group; lower sinus rhythm.
  • Despite anatomical and some echocardiographic differences, exercise performance and functional health status were comparable to non-heterotaxy survivors.

Conclusions:

  • Patients with heterotaxy after the Fontan procedure exhibit distinct characteristics and medical histories.
  • Anatomical differences and some echocardiographic/rhythm variations do not translate to significant differences in exercise performance or functional health.
  • This study provides insights into the profile of heterotaxy patients surviving the Fontan procedure.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...